Mark Jarek is a Rheumatology/Immunology physician. OpenAlex indexes 7 publications with 221 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3733 S Moonlit Ln
Republic, MO 657389448
Telephone
000-000-0000Provider last certified this registry record 21 Mar 2025.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202533 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.8%Folate Analog Metabolic Inhibitor12.9%Methotrexate97%Methotrexate Sodium3%Part D<11 patientsTNF inhibitor9.3%Humira(Cf) Pen28%Enbrel Sureclick28%Enbrel Mini11%Enbrel9%Cimzia (2 Pack)8%Humira Pen7%Humira(Cf)7%Simponi3%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
21.7%Corticosteroid15.9%Prednisone100%Part D≥189 patientsAminosalicylate3.7%Sulfasalazine69%Sulfasalazine Dr31%Part D≥21 patients+ 2 more classes in this area
Nervous system
14.5%Opioid Agonist7.8%Tramadol Hcl78%Oxycodone Hcl10%Oxycodone-Acetaminophen8%Morphine Sulfate Er4%Part D<11 patientsGabapentinoids2.9%Gabapentin77%Pregabalin23%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prospective use of intramuscular triamcinolone acetonide in pseudogout.
PubMed
1997 - Periorbital Edema and Meesʼ Lines in Systemic Lupus Erythematosus
JCR Journal of Clinical Rheumatology
1996
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”